3 ASX All Ords shares up 250% to 750% in a year

These are the stories that are the stuff of dreams for every single ASX All Ords shares investor.

Buying at the exact right time… to capture extraordinary share price growth… in a very short period.

So hard to do.

But we love the stories, right?

So, let’s share in the tales of these three ASX All Ords shares that have skyrocketed by between 250% (at worst) to 750% over the past 12 months alone.

The 3 ASX All Ords shares shooting the lights out

Cettire share price rockets 752%

ASX retail share Cettire Ltd (ASX: CTT) recorded the highest price growth of all 500 companies in the S&P/ASX All Ordinaries Index (ASX: XAO) in FY23.

To date, Cettire shares are up 752%. They closed at $3.38 on Tuesday, down 2.31% for the day.

Some brokers think the luxury brands online retailer can go further thanks to its growing sales.

Wilson Asset Management dealer Will Thompson says the ASX All Ords share is still a buy.

He says Cettire is “quite a small player in a big market, and they’re growing quickly”.

Latin Resources shares blow up 378%

The Latin Resources Ltd (ASX: LRS) share price was the best-performing ASX All Ords mining share in FY23.

Latin Resources shares are up 378% over the past year. On Tuesday, the stock closed at 33 cents, down 4.35% for the day.

The turbocharger for Latin Resources shares was an announcement in May from the lithium miner.

Latin Resources released an update on its flagship Salinas Lithium Project in Brazil that sent the share price to the moon (and so far, it hasn’t come back).

Also, in late June, the company confirmed discovery of a “district scale lithium corridor” at the project.

ASX biotech screams 250% higher

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is currently $13.91, after gaining 4.2% in Tuesday trading.

This ASX All Ords healthcare share has shot 254% higher over the past 12 months.

The key driver of the Neuren Pharmaceuticals share price rise is the US Food and Drug
Administration’s approval of Daybue, which is the first and only approved treatment for Rett syndrome.

The illness is a rare neurodevelopmental disorder affecting 6,000 to 9,000 people in the US.

Daybue is being marketed by Neuren’s US partner, Acadia Pharmaceuticals.

Foolish takeaway on these ASX All Ords shares

Skyrocketing share price stories are exciting to read.

But the reality is you need a higher risk tolerance if you want to chase these types of unusual and spectacular gains.

There’s next-to-no chance that ASX 200 blue chip shares are ever going to deliver these types of phenomenal annual price gains.

But you’ll likely sleep better at night by investing in reliable, slow-moving large-cap shares instead of small-cap stocks representative of young, growing companies that may or may not succeed.

All three ASX All Ords shares profiled above are small-caps, which means they have market capitalisations below $2 billion.

The ASX All Ords index closed Tuesday in the red, losing 0.2% on the day.